Challenging Times

We live in challenging times to confront the coronavirus pandemic and its impact on our healthcare systems, people’s lives, safety, and future wellbeing.

People needing care are either socially-distanced or connected at home.

We need to:
  • Connect and be their companions with socially supportive health guidance to avoid hospitalizations.
  • Gain clinical expertise in how these patients are managed, their predisposition to disease, and train our healthcare professionals to deliver, monitor, and evaluate patients’ health safely.
  • Ensure people receive reliable information to alleviate healthcare systems, be screened quickly, follow appropriate treatment plans, and connect with physicians personally for key appointments or real emergencies.

Lovexair: What matters?

Meaningful solutions: OUR AIM AS A CONSORTIUM

We provide meaningful solutions, grow capabilities for healthcare systems to protect, better manage, and empower their user communities.

How? In a exible, integrable, interoperable digital ecosystem that can:

  • Guide by trained and experienced clinical personnel who support patients who are socially empowered to participate, in their self-care from any location.
  • Grow this care delivery model as a validated, sustainable, scalable, global enterprise supported through collaborating networks.
  • Build advanced integrated IT: AI, graphics based on robust data sets for better decision-making: innovative treatment, health passports, smart disease management tools, and tracking.

Improvid Core Partners: Clinical, Educational, Digital and Social

Fundación Lovexair

  • Shane Fitch (CEO Fundación Lovexair)
  • Dr. Raquel Sebio

Fundació Hospital Universitari Vall d’Hebron – Institut de Recerca

  • Dr. Marco Inzitari
  • Dr. Laura Mónica Pérez Bazán
  • Dr. Carmina Castellano Tejedor
  • Dr. Agnieszka Lewko (PhD)

Fundacion Blanquerna

  • Dr. Jordi Vilaró
  • Mr. Rodrigo Torres-Castro
  • Dr. Joaquim Gea
  • Dr. Esther Barreiro

Fundacio Clinic per a La Recerca Biomédica

  • Dr. Sara Laxe MD
  • Dr. Jacobo Sellarés
  • Dr. Elena Gimeno-Santos

Imaginary Srl

  • Lucia Pannese

Azatec, Srl

  • Pietro Azzaro
  • Marco Proserpio

XYcare Ltd

  • Dr. Ian Rubin Medical Director
  • Jules Gaughan

Instytut Gruzlicy I Chorob Pluc, Lung Institute

  • Prof. Joanna Chorostowska-Wynimko
  • Dr. Aleksandra Jezela- Stanek
  • Marek Kram

Improvid: Aims to provide a sustainable response for people’s health

Internet sources can be misleading patients and their families on how they self-care e effectively or receive adequate treatment for their illness.

Reliable and safe information exchange and sign-up with agreement. Inadequate communication contributes to poor patient participation in treatment.

Health care deficiencies including miss and underdiagnosis. We want to improve information, understanding, integrate with EMRs or relevant devices.

Non-adherence to treatment is too common and post-discharge support limited capabilities, not adapted to current society or non-existent.

What is the plan?

Our aim is not to reinvent the wheel but build on existing know-how, shared resources, and experience from operational digital ecosystem HappyAir to:
Develop an fexible care model and protocol based on PROMS, data science, and clinical expertise, monitor progress, and analyse sequelae in a personalized way.
Discover and add value in genetics and science for better clinical understanding and management of patients with multi-morbidities, predisposition, cultural diversity.
Apply an advanced social-educational approach to providing digital content and care training, in a user-friendly manner.
Support our clinical sta and patients by building communities using the key features of TICs which:
  • Onboard and engage people with relevant, interesting content.
  • Promote and reward behaviour change in managing our health better.
  • Improve adherence for better clinical outcomes.

How? With Multistakeholder Partnering

This consortium brings together expertise in clinical, IT, academic, and patient organization involvement with experience in developing digital health resources, education, and social support related to complex clinical conditions.

Lovexair is active participating as a patient representative in global committees for digital health solutions development, innovative treatments, early detection, or determining better engagement in clinical trials with leading Industry partners.

Our 20 years of experience in respiratory chronic and rare disease, has cultivated numerous relations throughout industry leadership with advanced clinical and technology capabilities: plasma-derived therapies, pharma and biotherapeutics, vaccine – production, and early diagnostic testing resources for disease such as Alpha-1.